These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

113 related items for PubMed ID: 26978053

  • 1. [The use of spitomine (buspirone) in the combined therapy of panic disorder].
    Vasileva AV, Karavaeva TA, Poltorak SV, Chekhlaty EI.
    Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(11):63-71. PubMed ID: 26978053
    [Abstract] [Full Text] [Related]

  • 2. Study and course of the psychological profile in 77 patients expressing panic disorder with agoraphobia after cognitive behaviour therapy with or without buspirone.
    Bouvard M, Mollard E, Guerin J, Cottraux J.
    Psychother Psychosom; 1997; 66(1):27-32. PubMed ID: 8996712
    [Abstract] [Full Text] [Related]

  • 3. A controlled study of cognitive behaviour therapy with buspirone or placebo in panic disorder with agoraphobia.
    Cottraux J, Note ID, Cungi C, Légeron P, Heim F, Chneiweiss L, Bernard G, Bouvard M.
    Br J Psychiatry; 1995 Nov; 167(5):635-41. PubMed ID: 8564320
    [Abstract] [Full Text] [Related]

  • 4. [Clinical potential and possibilities of using buspirone in the treatment of anxiety disorders].
    Dzampaev AT, Suvorova IA, Damulin IV.
    Zh Nevrol Psikhiatr Im S S Korsakova; 2014 Nov; 114(8):94-104. PubMed ID: 25389538
    [Abstract] [Full Text] [Related]

  • 5. Interaction of pharmacological and psychological treatments of anxiety.
    Lader MH, Bond AJ.
    Br J Psychiatry Suppl; 1998 Nov; (34):42-8. PubMed ID: 9829016
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. A randomized effectiveness trial of cognitive-behavioral therapy and medication for primary care panic disorder.
    Roy-Byrne PP, Craske MG, Stein MB, Sullivan G, Bystritsky A, Katon W, Golinelli D, Sherbourne CD.
    Arch Gen Psychiatry; 2005 Mar; 62(3):290-8. PubMed ID: 15753242
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Treatment of panic disorder: nonbenzodiazepine anxiolytics, including buspirone.
    Robinson DS, Shrotriya RC, Alms DR, Messina M, Andary J.
    Psychopharmacol Bull; 1989 Mar; 25(1):21-6. PubMed ID: 2570437
    [No Abstract] [Full Text] [Related]

  • 14. [The use of buspirone in clinical practice].
    Levin OS.
    Zh Nevrol Psikhiatr Im S S Korsakova; 2015 Mar; 115(4):83-87. PubMed ID: 26288293
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Abecarnil for the treatment of generalized anxiety disorder: a placebo-controlled comparison of two dosage ranges of abecarnil and buspirone.
    Pollack MH, Worthington JJ, Manfro GG, Otto MW, Zucker BG.
    J Clin Psychiatry; 1997 Mar; 58 Suppl 11():19-23. PubMed ID: 9363044
    [Abstract] [Full Text] [Related]

  • 18. A risk-benefit assessment of buspirone in the treatment of anxiety disorders.
    Pecknold JC.
    Drug Saf; 1997 Feb; 16(2):118-32. PubMed ID: 9067123
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.